IR
Superintel
OverviewMarketsWatchlist
© 2026 IR SuperintelMethodologyContact

Lynx1 Capital Management LP

Q1 2024 Holdings

Filed 2024-05-15 | 1 holdings | $2.4M | 13F-HR/A | View on SEC ↗ · Holdings Table ↗

Amended (2024-05-30) | View on SEC ↗ · Holdings Table ↗

Sign in to see sub-manager breakdown

IssuerClassCUSIPValue ↓Shares% Portfolio
Alpine Immune Sciences Inc(NVLSEUR)COM02083G100$89.3M2,253,18323.2%
Merus N VCOMN5749R100$68.0M1,509,00717.6%
Stoke Therapeutics Inc(STOK)COM86150R107$49.9M3,696,82012.9%
Tscan Therapeutics Inc(TCRX)COM89854M101$41.5M5,224,60010.8%
Cabaletta BIO Inc(CABA)COM12674W109$35.5M2,082,9739.2%
GH Research PLC(GHRS)ORDINARY SHARESG3855L106$35.3M3,310,5639.1%
C4 Therapeutics Inc(CCCC)COM STK12529R107$29.7M3,634,6627.7%
Silence Therapeutics PLC(SLN)ADS82686Q101$11.4M526,6422.9%
Autolus Therapeutics PLC(AUTL)SPON ADS05280R100$8.9M1,390,1602.3%
Passage BIO IncCOM702712100$6.5M4,845,8711.7%
Kinnate Biopharma IncCOM49705R105$5.3M1,981,1061.4%
Ibio(IBIO)ACON NEW451033708$2.4M600,000100.0%
Nektar Therapeutics(NKTREUR)COM640268108$1.9M2,068,8420.5%
Pieris Pharmaceuticals IncCOM720795103$1.6M8,779,1620.4%
Bionomics Limited(BNOXN)ADS09063M205$838.9K814,4670.2%
Centessa Pharmaceuticals PLC(CNTA)SPONSORED ADS152309100$196.6K17,4000.1%